You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 19, 2024

Claims for Patent: 6,423,735

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 6,423,735

Title:	Compounds and methods for use thereof in the treatment of cancer or viral infections
Abstract:	Benzimidazole derivatives and salts and prodrugs thereof are disclosed, together with methods for the treatment of cancers or viral infections in warm blooded animals by administration of these compounds. Such compounds may be used in combination with a chemotherapeutic agent and/or a potentiator.
Inventor(s):	Camden; James Berger (West Chester, OH), Quada, Jr.; James C. (San Antonio, TX), Agyin; Joseph K. (San Antonio, TX)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	09/676,029
Patent Claims:	1. A method for treating cancer susceptible to treatment in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula A-4: ##STR11## wherein, R.sub.1 is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl. 2. A method according to claim 1 wherein said compound is in the form of a pharmaceutically acceptable salt thereof. 3. A method according to claim 2 wherein said pharmaceutically acceptable salt is hydrochloride salt. 4. A method according to claim 1 wherein said compound is in the form of a prodrug thereof. 5. A method according to claim 1 herein R.sub.1 is alkyl or substituted or unsubstituted phenyl. 6. A method according to claim 1 wherein said compound is micronized and is suitable for administering to said warm blooded animal by injection. 7. A method according to claim 1 wherein said compound is administered in an amount of from 10 mg/kg body weight to 10,000 mg/kg body weight. 8. A method according to claim 1 wherein said compound is administered orally, enterically, intravenously, peritoneally, or by injection. 9. A method according to claim 1 wherein said compound is administered in a pharmaceutically acceptable carrier. 10. A method according to claim 1 wherein said cancer is a carcinoma. 11. A method according to claim 1 wherein said cancer is leukemia. 12. A method according to claim 1 wherein said cancer is melanoma. 13. A method according to claim 1 wherein said cancer is colon cancer. 14. A method according to claim 1 wherein said cancer is breast cancer. 15. A method according to claim 1 wherein said cancer is lung cancer. 16. A method according to claim 1 wherein said cancer is pancreatic cancer. 17. A method according to claim 1 wherein said cancer is ovarian cancer. 18. A method according to claim 1 wherein said cancer is prostate cancer. 19. A method for treating cancer susceptible to treatment in a warm-blooded animal comprising administering to the warm-blooded animal a therapeutically effective amount of a compound of the following formula A-4: ##STR12## wherein, R.sub.1 is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl; and a therapeutically effective amount of a chemotherapeutic agent. 20. A method according to claim 19 which further comprises administering a potentiator. 21. A method for treating a viral infection in a warm-blooded animal comprising administering to the warm-blooded animal a safe and effective amount of a compound of the following formula A-4: ##STR13## wherein, R.sub.1 is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl. 22. A method according to claim 9 wherein said pharmaceutically acceptable carrier is a liposome delivery system. 23. A method according to claim 9 wherein said pharmaceutically acceptable carrier is a soluble polymer to which said compound is coupled. 24. A method according to claim 9 wherein said pharmaceutically acceptable carrier is a biodegradable polymer to which said compound is coupled. 25. A method according to claim 19 wherein said chemotherapeutic agent is selected from the group consisting of a DNA-interactive agent, an antimetabolite, a tubulin-interactive agent, a hormonal agent, an antihormonal antigen, and an adrenal corticosteroid. 26. A method according to claim 19 wherein said chemotherapeutic agent is selected from the group consisting of hydroxyurea, asparaginase, and paclitaxel. 27. A method according to claim 21 wherein said compound is micronized and is suitable for administering to said warm blooded animal by injection. 28. A method according to claim 21 wherein said compound is administered in an amount of from 10 mg/kg body weight to 10,000 mg/kg body weight. 29. A method according to claim 21 wherein said compound is administered orally, enterically, intravenously, peritoneally, or by injection. 30. A method according to claim 21 wherein said compound is administered in a pharmaceutically acceptable carrier. 31. A method according to claim 30 wherein said pharmaceutically acceptable carrier selected from the group consisting of a liposome delivery system, a soluble polymer to which said compound is coupled, and a biodegradable polymer to which said compound is coupled. 32. A method according to claim 21 wherein said compound is in the form of a pharmaceutically acceptable salt thereof. 33. A method according to claim 21 wherein said compound is in the form of a prodrug thereof.

Details for Patent 6,423,735

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	ELSPAR	asparaginase	For Injection	101063	01/10/1978	⤷ Try a Trial	2017-05-16
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.